Skip to main content
Log in

Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis

  • ORIGINAL PAPER
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Biliary pseudolithiasis has been reported in patients who received ceftriaxone therapy. In addition to biliary sludge formation occasional reports of ceftriaxone-induced nephrolithiasis have been published. In general, these adverse effects will develop after seven to ten days of treatment. We report on a seven-year-old boy with ceftriaxone-associated biliary pseudolithiasis and nephrolithiasis four days after initiation of treatment. Patients receiving a high dose of ceftriaxone and developing colicky abdominal pain should be considered for ultrasound and a change in antibiotic therapy if appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 16 February 1999 / Accepted: 9 June 1999

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Moor, R., Egberts, A. & Schröder, C. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr 158, 975–977 (1999). https://doi.org/10.1007/s004310051261

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004310051261

Navigation